Log In
Print
BCIQ
Print
Print this Print this
 

Copaxone, glatiramer acetate

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionSelective major histocompatibility complex class II (MHCII) modulator
Molecular Target Major histocompatibility complex class II (MHCII)
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentMarketed
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat clinically isolated syndrome (CIS) suggestive of MS; Treat exacerbating/remitting multiple sclerosis (MS); Treat multiple sclerosis (MS); Treat patients who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with multiple sclerosis (MS); Treat relapsing multiple sclerosis (MS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation

Partner

Sanofi; Takeda Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today